EPCAM and hepatocellular carcinoma: In hepatocellular carcinoma (HCC) cells expressing the liver CSC marker EpCAM, inhibition of mTOR complex 2 (mTORC2) or activation of mTORC1 leads to reduced EpCAM expression, thereby decreasing the tumorigenic potential of CSCs and increasing sensitivity to the antiproliferative effects of 5-FU.